Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritavancin for CIED Infections
NCT07013552Not yet recruiting
- Sponsor
- Medical University of Silesia
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of oritavancin in cardiac implantable electronic device infection (CIEDI) (2 arms), sponsored by Medical University of Silesia. Primary endpoints: Complete Cure Rate at 3 months and Treatment-related Serious Adverse Events at 3 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
oritavancin
03
Conditions
cardiac implantable electronic device infection (CIEDI)
Beyond the preview
Go deeper on NCT07013552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013552.